Biliary cancer
Conditions
Interventions
None listed
Sponsors
The Hepatobiliary and Pancreatic Oncology (HBPO) Group of the Japan Clinical Oncology Group (JCOG)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who fulfills all the following inclusion criteria 1) The patient is diagnosed with adenocarcinoma of biliary tract by pathological examination of resected or pre-/intra- operative biopsied specimen (The pathological diagnosis is conducted according to the sixth edition of General Rules for the Clinical and Pathological Study of Primary Liver Cancer in intrahepatic bile duct cancer, and according to the sixth edition of Classification of Biliary Tract Cancers in other biliary cancers) 2) The patients who underwent the contrast-enhanced multidetector-row computed tomography (MDCT) examination (5mm or less slice, regardless the presence or absence of biliary drainage) within 60 days before operation, and were diagnosed with resectable biliary cancer (without distant metastasis and R0/1 resection possible) 3) The patients underwent laparotomy with the intent of tumor resection between 2014 and 2016 in the institution of JCOG (including not only the resected cases but also the unresected cases) 4) The patients do not have a past history of either preoperative chemotherapy or radiation therapy in the upper abdomen
Exclusion criteria
Exclusion criteria: 1) The patients with intrahepatic bile duct cancer with the macroscopic appearance of periductal infiltrating type, intraductal-growth type or predominant type of either, because General Rules for the Clinical and Pathological Study of Primary Liver Cancer is not applied to these types. 2) The patients who underwent preoperative image examination only in other hospital 3) The patents who have other active cancers at the time of operation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of pathological stage I (stage IA in distal bile duct cancer) among the patients who were diagnosed with a biliary cancer that fulfills the inclusion criteria of preoperative therapy trial on MDCT | — |
Secondary
| Measure | Time frame |
|---|---|
| Sensitivity and specificity of MDCT to diagnose a biliary cancer that fulfills the inclusion criteria of preoperative therapy trial; Sensitivity and specificity of MDCT to diagnose the lymph node metastasis; Sensitivity and specificity of MDCT to diagnose the R1 (invasive cancer) or R2 resection | — |
Countries
Japan
Contacts
Public ContactSatoshi Nara
National Cancer Center Hospital Hepatobiliary and Pancreatic Surgery Division
Outcome results
None listed